[go: up one dir, main page]

WO2011045774A3 - Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation - Google Patents

Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation Download PDF

Info

Publication number
WO2011045774A3
WO2011045774A3 PCT/IB2010/054714 IB2010054714W WO2011045774A3 WO 2011045774 A3 WO2011045774 A3 WO 2011045774A3 IB 2010054714 W IB2010054714 W IB 2010054714W WO 2011045774 A3 WO2011045774 A3 WO 2011045774A3
Authority
WO
WIPO (PCT)
Prior art keywords
paliperidone
preparation
pharmaceutical compositions
extended release
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/054714
Other languages
English (en)
Other versions
WO2011045774A4 (fr
WO2011045774A2 (fr
Inventor
Kumaravel Vivek
Rajan Kumar Verma
Romi Barat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to EP10773995.5A priority Critical patent/EP2488162A2/fr
Priority to AU2010308021A priority patent/AU2010308021A1/en
Priority to US13/502,016 priority patent/US20130129827A1/en
Priority to CA2777856A priority patent/CA2777856A1/fr
Publication of WO2011045774A2 publication Critical patent/WO2011045774A2/fr
Publication of WO2011045774A3 publication Critical patent/WO2011045774A3/fr
Publication of WO2011045774A4 publication Critical patent/WO2011045774A4/fr
Anticipated expiration legal-status Critical
Priority to ZA2012/03176A priority patent/ZA201203176B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à libération prolongée de palipéridone et leur procédé de préparation.
PCT/IB2010/054714 2009-10-16 2010-10-18 Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation Ceased WO2011045774A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10773995.5A EP2488162A2 (fr) 2009-10-16 2010-10-18 Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation
AU2010308021A AU2010308021A1 (en) 2009-10-16 2010-10-18 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
US13/502,016 US20130129827A1 (en) 2009-10-16 2010-10-18 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
CA2777856A CA2777856A1 (fr) 2009-10-16 2010-10-18 Compositions pharmaceutiques a liberation prolongee de paliperidone et leurs procedes de preparation
ZA2012/03176A ZA201203176B (en) 2009-10-16 2012-05-02 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2150DE2009 2009-10-16
IN2150/DEL/2009 2009-10-16

Publications (3)

Publication Number Publication Date
WO2011045774A2 WO2011045774A2 (fr) 2011-04-21
WO2011045774A3 true WO2011045774A3 (fr) 2011-06-16
WO2011045774A4 WO2011045774A4 (fr) 2011-08-11

Family

ID=43413726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054714 Ceased WO2011045774A2 (fr) 2009-10-16 2010-10-18 Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation

Country Status (6)

Country Link
US (1) US20130129827A1 (fr)
EP (1) EP2488162A2 (fr)
AU (1) AU2010308021A1 (fr)
CA (1) CA2777856A1 (fr)
WO (1) WO2011045774A2 (fr)
ZA (1) ZA201203176B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034605A1 (en) * 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
US20160193155A1 (en) * 2013-09-02 2016-07-07 Sun Pharmaceutical Industries Limited Pulsatile-release dosage form
GR1008842B (el) * 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
EP3439638A1 (fr) * 2016-04-05 2019-02-13 Pharmathen S.A. Composition pharmaceutique comprenant un agent antipsychotique atypique et son procédé de préparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010981A1 (fr) * 2002-07-29 2004-02-05 Alza Corporation Techniques et formes de dose d'apport commande de paliperidone
WO2009025859A1 (fr) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Formulation à libération prolongée de palipéridone
WO2009109993A1 (fr) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Forme pharmaceutique à libération prolongée de palipéridone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2354472C (fr) 1998-12-17 2009-02-24 Alza Corporation Transformation de capsules de gelatine remplies de fluide en systemes a liberation regulee a l'aide de revetements multiples
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010981A1 (fr) * 2002-07-29 2004-02-05 Alza Corporation Techniques et formes de dose d'apport commande de paliperidone
WO2009025859A1 (fr) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Formulation à libération prolongée de palipéridone
WO2009109993A1 (fr) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Forme pharmaceutique à libération prolongée de palipéridone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRAMER M ET AL: "Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, WILLIAMS AND WILKINS, US, vol. 27, no. 1, 1 February 2007 (2007-02-01), pages 6 - 14, XP009087471, ISSN: 0271-0749, DOI: DOI:10.1097/JCP.0B013E31802DDA4A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic

Also Published As

Publication number Publication date
US20130129827A1 (en) 2013-05-23
WO2011045774A4 (fr) 2011-08-11
CA2777856A1 (fr) 2011-04-21
ZA201203176B (en) 2013-01-30
WO2011045774A2 (fr) 2011-04-21
AU2010308021A1 (en) 2012-05-17
EP2488162A2 (fr) 2012-08-22

Similar Documents

Publication Publication Date Title
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
IL209258A (en) Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses
IL214396A (en) Anti-viral anti-viral nucleosides, pharmaceutical preparations containing them and methods for their preparation, as well as their preparation of antiviral intermediates
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL218370A0 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen, processes for producing the same and uses thereof
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
IL248510A0 (en) A process for preparing sustained release pharmaceutical preparations of somatostatin analogs
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2012015999A3 (fr) Procédé de préparation de mésylate d'imatinib
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2009094457A3 (fr) Benzhydryléthers substitués
WO2010065586A3 (fr) Préparation de capécitabine
WO2011045760A3 (fr) Compositions d'olmésartan médoxomil micronisé
EP2300467A4 (fr) Nouveaux procédés améliorés de préparation de la palipéridone
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
WO2011045774A3 (fr) Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation
MX339361B (es) Derivados de alternano.
ZA201303692B (en) Diphenyl-amine derivatives:uses,process of synthesis and pharmaceutical compositions
WO2011095985A3 (fr) Sels de rasagiline et procédés de preparation de ces derniers
WO2011138797A3 (fr) Composition pharmaceutique de lansoprazole à action différée se désintégrant par la voie buccale
WO2011100282A3 (fr) Polymorphes de mésylate d'imatinib
WO2011107921A3 (fr) Composition de milnacipran à libération modifiée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10773995

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2777856

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010308021

Country of ref document: AU

Ref document number: 2010773995

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4235/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010308021

Country of ref document: AU

Date of ref document: 20101018

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13502016

Country of ref document: US